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Abstract 
Background: Accurate assessment of balance and gait is necessary to monitor the clinical progress of Parkinson’s 
disease (PD). Conventional clinical scales can be biased and have limited accuracy. Novel interactive devices are 
potentially useful to detect subtle posture or gait-related impairments.
Methods: Posturographic and single and dual-task gait assessments were performed to 54 individuals with PD and 
43 healthy controls with the Wii Balance Board and the Kinect v2 and the, respectively. Individuals with PD were also 
assessed with the Tinetti Performance Oriented Mobility Assessment, the Functional Gait Assessment and the 10-m 
Walking Test. The influence of demographic and clinical variables on the performance in the instrumented posturo-
graphic and gait tests, the sensitivity of these tests to the clinical condition and phenotypes, and their convergent 
validity with clinical scales were investigated.
Results: Individuals with PD in H&Y I and I.5 stages showed similar performance to controls. The greatest differences 
in posture and gait were found between subjects in H&Y II.5 and H&Y I–I.5 stage, as well as controls. Dual-tasking 
enhanced the differences among all groups in gait parameters. Akinetic/rigid phenotype showed worse postural con-
trol and gait than other phenotypes. High significant correlations were found between the limits of stability and most 
of gait parameters with the clinical scales.
Conclusions: Low-cost devices showed potential to objectively quantify posture and gait in established PD 
(H&Y ≥ II). Dual-tasking gait evaluation was more sensitive to detect differences among PD stages and compared to 
controls than free gait. Gait and posture were more impaired in akinetic/rigid PD.
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Background
Parkinson’s disease (PD) is a neurodegenerative dis-
ease, characterized by motor impairments with par-
ticular impacts on posture and gait, leading to postural 
instability and falls [1]. Previous PD research has 
described an overall decline in gait associated with 
neurodegeneration. Although gait does not appear to 
differ significantly between PD patients and healthy 
controls during the early stages of PD, including those 
categorized as Hoehn and Yahr (H&Y) I–II.5 [2], wors-
ening gait speeds are expected across all H&Y stages 
and become especially evident in patients during the 
moderate and severe stages, including those catego-
rized as H&Y ≥ II.5 [3]. In addition to an association 
with the time course of clinical symptoms, worsening 
spatiotemporal gait parameters have been identified 
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in individuals with akinetic/rigid (AR)- or freezing-
PD phenotypes [4, 5]. Research has also demonstrated 
that the performance of dual tasks has a significant and 
consistent negative effect on gait performance in PD 
patients, at different gait speeds and for different tasks 
[6], and dual-task associated gait evaluation can be 
used to distinguish individuals with de novo PD from 
healthy controls, which is not possible through the 
evaluation of regular walking [7]. Standardized clinical 
scales are commonly used to assess posture and gait in 
clinical settings, but their limited accuracy and intrin-
sic subjectivity may dramatically reduce their reliability 
[8]. To overcome these limitations, different instru-
mented tools, such as force plates and motion-tracking 
systems, have been developed for the accurate assess-
ment of posture and gait, respectively [9, 10]. However, 
instrumented systems can be time- and space-consum-
ing and are often unaffordable for most clinics, limiting 
their widespread use. Recent low-cost interactive tech-
nologies have shown comparable accuracy to labora-
tory-grade instrumented systems while being portable 
and affordable [11–13].
Wearable sensors that embed accelerometers and gyro-
scopes have been widely used to investigate posture and 
gait in subjects with PD [14, 15]. However, the accuracy 
of the assessment using wearable sensors depends on 
sensor location, sensor-to-segment alignment, and, fre-
quently, on the number of sensors, which increases the 
total cost and obtrusiveness of the setting [16]. The Wii 
Balance Board (WBB) (Nintendo, Kyoto, Japan) and the 
Kinect for Windows v2, also known as Kinect v2 (Micro-
soft, Redmond, WA, USA), in contrast, potentially enable 
human motion tracking without the limitations of wear-
able sensors. The WBB is a portable and low-cost force 
platform that can estimate the center of pressure with 
comparable accuracy to that of laboratory-grade systems 
[17]. Preliminary research involving individuals with dif-
ferent neurological diseases, including PD, and different 
laboratory-grade systems has also shown that the WBB is 
a valid and feasible tool for the measurement of postural 
control and static balance during these conditions [18–
20]. The low-cost, infrared camera Kinect v2 enables the 
motion tracking of the main joints of the human body, 
without requiring wearable markers. The potential for the 
Kinect v2 to determine the spatiotemporal and kinematic 
variables associated with gait has been also investigated 
in patients with neurological diseases, with promising 
results [21–25]. Research has also shown good agreement 
between the Kinect and a laboratory-grade three-dimen-
sional motion analysis system during measurements of 
movements of individuals with PD [26]. However, exist-
ing studies examining individuals with PD have included 
limited numbers of participants [21, 22, 25], which limits 
the ability to extrapolate results, or have only investigated 
specific parameters, without performing comprehensive 
postural or gait assessments [21, 22, 25].
We hypothesized that the WBB and the Kinect v2 can 
be used as sensitive and valid tools for the identification 
of postural and gait disturbances, which are present at 
PD onset in most individuals. The aim of this study was 
to determine the sensitivity of these tools for the evalu-
ation of impairments associated with the clinical condi-
tion and phenotype of PD patients, and their convergent 
validity with conventional clinical scales.
Methods
Participants
A convenient sample of individuals with PD were 
recruited from the Movement Disorders Unit of the Hos-
pital Universitari Mútua de Terrassa (Terrassa, Barcelona, 
Spain), from January 2017 to November 2018. Individuals 
were included if they met the UK Brain Bank criteria for 
PD [27], were categorized on the modified H&Y scale as 
stages I–III [28], were able to walk 5 m without assistance 
or device, and did not present dyskinesia or significant 
cognitive impairments, as defined by scores > 18, 21, or 24 
on the Mini-Mental State Examination, depending on the 
individual education level [29], at the time of evaluation.
Healthy participants, with no concurrent neurological 
or systemic disorders, postural or gait impairments, or 
lower limb prostheses, were primarily recruited among 
the relatives and caregivers of participants with PD.
Written informed consent was obtained from all par-
ticipants, and the present study was approved by the 
Ethics Committee of the University Hospital Mútua de 
Terrassa.
Instrumentation
Postural control was assessed using a WBB-based pos-
turography application, which included a modified clini-
cal test of sensory interaction on balance (mCTSIB) and 
a limits of stability (LOS) test [19]. The mCTSIB inves-
tigated alterations in the sensory integration and pro-
cessing, as a measure of sway, by analyzing variations in 
the center of pressure while barefoot subjects remained 
as still as possible, in a standing position, for 30 s, under 
four different sensorial conditions: eyes opened and 
closed on the platform and eyes opened and closed on 
a piece of foam over the platform. The LOS test quanti-
fied the maximum displacement achievable for the center 
of pressure while maintaining contact between the soles 
of the feet and the platform, in eight directions, and the 
reaction time necessary to initiate the movement.
Spatiotemporal gait features were assessed with a 
Kinect v2-based gait analysis application [30], which 
required participants to walk towards the Kinect v2 at 
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least three times, from a distance of 6 m, and estimated 
the most widely-used spatiotemporal and kinematic gait 
parameters; toe kinematics were not assessed using this 
application due to poor reliability [22, 31].
A WBB and a Kinect v2 were used to estimate the 
center of pressure of the participants and to retrieve the 
3-dimensional body pose of participants, respectively. A 
conventional laptop was used to run both applications.
Procedure
All participants with PD underwent a complete neurolog-
ical evaluation, including the collection of demographic 
and clinical data, and were categorized by neurologists 
(MA, PP) into tremor dominant (TD), akinetic/rigid (AR) 
or mixed (MX) phenotypes as described previously [32, 
33] (Table  1). Individuals with PD were also assessed 
using a battery of clinical scales, including the Unified 
Parkinson’s Disease Rating Scale (UPDRS) [34], the Neu-
ropsychiatric Inventory Questionnaire [35], the Non-
Motor Symptoms Scale [36], the modified-Minnesota 
Impulsive Disorders Interview [37], the 39-Item Parkin-
son’s Disease Questionnaire [38], the Tinetti Performance 
Oriented Mobility Assessment [8], the Functional Gait 
Assessment [8], and the 10-m Walking Test [39]. Finally, 
all participants, including those with PD and healthy sub-
jects, were assessed by the instrumented posturography 
and gait analysis applications. For the dual-task condi-
tion, subjects were instructed to walk towards the camera 
while simultaneously counting backward from a number 
randomly picked between 60 and 110, either by ones, by 
twos (odd and even), by threes, or by sevens, according to 
the educational level and individual capabilities of each 
participant, which were assessed before the experiment. 
Subjects were allowed to rest between tests if needed.
All assessments occurred in a dedicated room, free 
of distractors, and were performed by the same experi-
menter. The laptop used to run the applications was 
placed on a table, at a height of 80  cm. The Kinect v2 
was placed on the table in front of the laptop, pointing 
towards the room. The WBB was situated on the floor, 
1.5 m away from the table.
Data analysis
Participants with PD were categorized into three groups, 
according to their H&Y scores: I–I.5, II, and II.5 [28]. 
Because only two participants were scored as H&Y I.5, 
they were merged into the H&Y I group. The mean value 
of each postural parameter was defined as the mean value 
of each subtest, to ensure the homogeneity of subjects’ 
data.
Multiple regression analyses were performed to 
evaluate the influences of age, sex, education, height, 
weight, and disease duration on posturographic and gait 
measurements during the single-task condition. Demo-
graphic and clinical differences between groups were 
investigated using analysis of variance (ANOVA) and 
frequency analyses, applying Bonferroni and Cramer’s V 
post hoc corrections to quantitative and qualitative vari-
ables, respectively. Student’s t-tests and ANOVA analyses 
were also used to evaluate differences between all meas-
ures of postural control and gait, including (1) between 
controls and all individuals with PD; (2) between controls 
and the H&Y I–I.5, II, and II.5 groups, separately; (3) 
among the H&Y groups; and (4) among groups of par-
ticipants with different phenotypes. Post hoc Bonferroni 
correction was applied to all ANOVA tests. The conver-
gent validity of measurements made using instrumented 
posturography and gait analyses and those made using 
conventional scales was determined using Pearson’s cor-




Fifty-four individuals with PD (11 individuals in stage 
I–I.5, 37 individuals in stage II, and 6 individuals in stage 
II.5) and 43 healthy controls participated in the study.
The three groups of participants with PD demon-
strated significantly different scores for subparts II and 
III of the UPDRS and for the lower body sub-items of 
part III (Table 1). Significant differences were also found 
among these groups for disease duration and the scores 
on the Non-Motor Symptoms Scale, the Tinetti Perfor-
mance Oriented Mobility Assessment, the Functional 
Gait Assessment, and the 10-m Walking Test. Other 
demographic and clinical varia bles showed no signifi-
cant differences, supporting the existence of inter-group 
homogeneity. Phenotypes were similarly distributed 
among groups. Forty-four participants (81.4%) were 
being treated with levodopa (Table 1).
Twenty-five healthy women (58%) and 18 men (42%), 
with a mean age of 67.84 years, participated in the study 
and completed the posturographic and gait assessments. 
All participants completed all the tests. Data from three 
healthy participants during the dual-task gait condi-
tion could not be retrieved and were not included in the 
analysis.
Influence of demographic and clinical variables
Regression analyses showed the statistically signifi-
cant influences of age on the mean displacement dur-
ing LOS (β = − 0.461; p = 0.002), gait speed (β = − 0.446; 
p = 0.002), cadence (β = 0.384; p = 0.030), and stride time 
(β = 0.438; p = 0.009), of height on gait speed (β = 0.465; 
p = 0.001) and stride length (β = 0.473; p = 0.002), and of 
weight on stride width (β = 0.592; p < 0.001).
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Table 1 Demographic and clinical characteristics of the participants with Parkinson’s disease
Characteristics of participants with Parkinson’s disease, grouped by their clinical progress. Data are presented as mean ± SD or n (%). H&Y: Hoehn & Yahr
*Evaluated with the Unified Parkinson’s Disease Rating Scale
a Significantly different from H&YII (p < 0.05)
b Significantly different from H&Y II.5 (p < 0.05)
c Significantly different from H&Y II (p < 0.01)
d Significantly different from H&Y II.5 (p < 0.01)
H&Y I-I.5 H&Y II H&Y II.5
Number of participants (n) 11 37 6
Age (years) 68.0 ± 11.8 68.7 ± 10.2 74.5 ± 8.9
Sex (n, %)
 Women 2 (18.2%) 18 (48.6%) 4 (66.7%)
 Men 9 (81.8%) 19 (51.4%) 2 (33.3%)
Height (cm) 170.2 ± 9.4 164.2 ± 6.2 162.2 ± 8.3
Weight (kg) 79.3 ± 15.4 72.1 ± 14.9 75.0 ± 11.7
Education level (years) 9.0 ± 5.7 9.0 ± 4.3 5.5 ± 3.2
Disease duration (years) 3.8 ± 2.1 6.7 ± 4.0 8.9 ± 5.6
Phenotype (n, %)
 Tremor dominant 6 (54.5%) 18 (48.6%) 3 (50.0%)
 Akinetic/rigid 2 (18.2%) 6 (16.2%) 2 (33.3%)
 Mixed 3 (27.3%) 13 (35.1%) 1 (16.7%)
Positive ioflupane I123 injection test (n) 5 out of 5 (100%) 12 out of 15 (80%) 2 out of 2 (100%)
Movement disorders*
 Tremor type
  Postural 5 (45.5%) 9 (24.3%) 1 (16.7%)
  Rest 2 (18.2%) 6 (16.2%) 2 (33.3%)
  Both 3 (27.3%) 19 (51.4%) 2 (33.3%)
 Freezing 0 9 (24.3%) 1 (16.7%)
 Festination 2 (18.2%) 8 (21.6%) 2 (33.3%)
 Dyskinesia 0 6 (16.2%) 0
 Fallers 1 (9.1%) 8 (21.6%) 2 (33.3%)
Schwab & England Activities of Daily Living Scale (100%) (n) 11 (100%) 24 (64.9%) 4 (66.7%)
REM Sleep Behavior Disorder (n) 4 (36.4%) 21 (56.8%) 1 (16.7%)
Unified Parkinson’s Disease Rating Scale
 I. Mentation, Behavior And mood 1.4 ± 1.4 2.5 ± 2.3 1.8 ± 1.8
 II. Activities of daily living 2.2 ± 1.42.3 7.4 ± 4.2 7.3 ± 3.1
 III. Motor examination 8.4 ± 4.02.3 18.7 ± 7.5 16.8 ± 4.6
 III. Motor examination (lower body) 2.2 ± 1.51 3.9 ± 1.9 4.6 ± 1.5
Mini Mental State Examination 27.18 ± 2.5 27.18 ± 2.5 24.50 ± 2.4
modified Minnesota Impulsive Disorders Interview 0.0 ± 0.0 2.05 ± 4.7 1.00 ± 2.4
39-item Parkinson’s Disease Questionnaire (%) 3.68 ± 2.9 14.07 ± 15.3 17.43 ± 14.3
Non-Motor Symptoms Scale 13.36 ± 12.6a 34.86 ± 24.1 27.50 ± 15.4
Tinetti Performance Oriented Mobility Assessment
 Total 27.73 ± 0.5d 26.68 ± 1.6b 24.83 ± 2.4
 Balance subscale 15.73 ± 0.5d 15.35 ± 0.9b 14.17 ± 1.3
 Gait subscale 12.00 ± 0.0b 11.32 ± 0.9 10.67 ± 1.2
Functional Gait Assessment 27.91 ± 2.5d 25.68 ± 3.0d 20.83 ± 4.9
10-m Walking Test (s) 4.50 ± 0.7d 5.52 ± 1.2 6.68 ± 2.0
Levodopa currently treated (n, %) 3 (27.3%) 33 (89.2%) 6 (100%)
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Sensitivity to clinical conditions
When the group containing all individuals with PD was 
analyzed, increased sway was observed compared with 
the healthy subject group, but no other statistically signif-
icant differences in the LOS or gait-related variables were 
found (Table  2). The in-depth analysis of participants 
with PD, when grouped by H&Y stage, showed the pro-
gressive decline of postural control and gait with increas-
ing H&Y stages. The participants categorized as H&Y II 
showed the worst performance for all postural and gait 
measurements among the three groups. In contrast, par-
ticipants categorized as H&Y I–I.5 not only showed bet-
ter performance than individuals with more advanced 
pathological stages but also outperformed healthy sub-
jects, including decreased sway and increased LOS and 
gait speed values (Table 2).
The additional cognitive demands required during 
dual-task execution resulted in deleterious effects for all 
gait measurements, in both healthy subjects and indi-
viduals with PD. Similar to the observed effects on regu-
lar walking when participants with PD were considered 
alone, all gait measurements during the dual-task con-
dition were reduced for higher H&Y stages. However, 
dual-tasking showed larger differences when groups of 
participants were compared with healthy subjects, and 
gait speed differences were detected among the groups of 
participants (Table 2).
Sensitivity to phenotype
Individuals with the AR phenotype showed decreased 
LOS values compared with those for participants with 
the TD and MX phenotypes. Specifically, individuals 
with the AR phenotype had lower mean maximum dis-
placement values than those with the TD and MX phe-
notypes (7.07 vs 8.59 and 8.78 cm, respectively; corrected 
p < 0.05, in both cases), and greater mean reaction times 
(1.73 vs 1.07 and 0.98  s, respectively; corrected p < 0.01, 
in both cases). Although individuals with the AR pheno-
type showed consistently worse performance for all gait 
parameters, no other statistically significant differences 
in postural or gait measurements were found. Similarly, 
the effect of dual-task conditions on gait performance 
appeared to be more detrimental for patients with the 
AR phenotype, but no significant differences were found 
according to phenotype.
Convergent validity
Significant correlations were found between the mean 
displacement and mean reaction times for LOS and the 
conventional motor scales. No other significant correla-
tions emerged (Table 3).
All instrumented gait parameters during the single-task 
condition, except for stride width, showed significant 
correlations with conventional clinical scales, with vari-
able strengths. Among these correlations, the strong-
est interactions were found for the 10-m Walking Test, 
which ranged from good to excellent. Independent of 
correlation strengths, the signs of the correlations were 
all coherent, and indicated that better performances on 
all postural and gait parameters were correlated with bet-
ter performances on the clinical scales.
Discussion
In the present study, we investigated the use of the 
WBB and the Kinect v2 for the comprehensive analy-
sis of posture and gait in PD, focusing on the influence 
of demographic and clinical variables on postural- and 
gait-related parameters, the relationships between pos-
tural- and gait-related parameters, clinical conditions, 
and PD phenotype, and the convergent validity of these 
assessments with clinical scales. We found that postural 
and gait parameters were differentially influenced by 
age, height, and weight. Participants with PD showed 
impaired sway when compared with healthy controls, 
and a progressive decline in sway was associated with 
disease worsening. Patients with the AR phenotype had 
the worst performance among the groups. Different cor-
relations with coherent and variable strengths were found 
between the posture and gait-related parameters assessed 
using the instrumented posturography applications and 
clinical scales.
The effects of demographical variables on posture and 
gait that were detected in our study are supported by the 
findings of previous studies, which highlighted age as an 
unavoidably deleterious factor [40–42], associated with 
cognitive, muscular, and structural changes. The height-
related advantages in gait performance observed during 
our study have been also reported previously for indi-
viduals in similar age ranges as our participants, although 
this association appears to lose relevance beyond 80 years 
of age [43]. Similarly, previous studies have identified 
weight as a factor that influences stride performance [44], 
which supports the results found in our study.
The increased sway detected during advanced patho-
logical stages has been repeatedly reported [45–47] and 
is supported by a recent review, which identified this fea-
ture as one of the five primary control systems, together 
with the LOS [48]. Reduced LOS has also been previously 
described for PD patients [49] and has been associated 
with an increased risk of falling [50, 51]. The postural 
assessments performed during our study also demon-
strated reduced LOS in participants with PD, which 
increased with disease progression, but failed to reveal 
statistical significant differences between PD patients and 
healthy controls, likely due to the limited number of par-
ticipants in H&Y stages > II. The differences found during 
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this study between individuals classified as H&Y I–I.5 
and those in other stages may be due to the abnormal 
performance of the H&Y I–I.5 group in this study, which 
was improved even compared with healthy controls.
Instrumented gait assessment using the Kinect v2 suc-
cessfully differentiated H&Y II.5-stage PD participants 
from healthy controls during both single and dual-task 
conditions for all gait parameters, except stride width. As 
previously reported [6], walking parameters deteriorated 
during the dual-task condition in this study. The nega-
tive effects of dual-tasking were evident for both healthy 
controls and individuals with PD, for all gait parameters, 
except stride width. The absence of changes in stride 
width during both conditions is supported by a previous 
study, which reported comparable results among indi-
viduals with PD, both with and without cognitive impair-
ments [52]. The additional cognitive demands of the 
dual-task condition had a larger effect on PD patients in 
comparison to healthy subjects, which is also consistent 
with previous reports [53, 54]. The observed enhance-
ment of gait disturbances during the dual-task condition 
has been explained as a consequence of the activation 
of parallel processes in frontal attentional areas, which 
interferes with basal gait commands [55]. Such interfer-
ence could be less pronounced during the early stages of 
PD when cognition is generally well-enough preserved to 
over-compensate for this attentional interference [56, 57]. 
All these results under the dual-task condition should be 
taken into account considering that parameters of single-
task walking have been reported to be more accurate and 
have less variability for predicting the progression of the 
pathology [58].
The performances of H&Y I-I.5 PD patients observed 
in our study are comparable to those reported in previ-
ous studies [22, 59]. Other studies have reported a lack 
of significant balance or gait alterations during the early 
stages of PD [3, 59], which may indicate the development 
of compensatory mechanisms during the early stages of 
pathology. This abnormal performance could be also 
explained by the Hawthorne effect, which describes how 
a subject’s awareness of being observed can motivate an 
improved performance [60]. Specific analysis of other gait 
features could have improved the sensitive of the Kinect 
v2 to the motor differences among early stages of PD. 
First, reduced arm swing has been identified as a clinical 
feature of early stages of PD that can be evidenced using 
instruments, such as inertial sensors [61] and even with 
the Kinect [62]. Second, dynamic postural control dur-
ing turning has been also shown to be altered even in the 
early stages of PD, which can be evidenced with a motion 
analysis system [63]. Third, subjects in early stages of 
PD can also have difficulties to maintain a steady gait 
rhythm, which can manifest as an increased stride-to-
stride variability [5, 64]. Future studies should investigate 
the ability of the Kinect v2 to detect these motor features 
in early stages of PD, which might be even motor mark-
ers of prodromal PD [61]. A few studies have identified 
differences in gait performance between individuals with 
the AR phenotype and those with other phenotypes, such 
as decreased speed and stride compared with those with 
Table 3 Convergent validity between instrumented measures and conventional scales
Correlations between measures of the instrumented tests and conventional clinical scales
*p < 0.05. **p < 0.01





 Modified clinical test of sensory interaction on balance
  Speed − .183 − .24 − .088 − .154 .13
 Limits of stability
  Maximum displacement .484** .413** .455** .516** − .506**
  Reaction time − .354** − .369** − 0.265 − .501** .279*
Gait (single-task)
 Gait speed .521** .509** .422** .766** − .850**
 Cadence .447** .434** .364** .594** − .698**
 Stride length .385** .360** .329* .594** − .655**
 Stride time − .458** − .455** − .363** − .645** .750**
 Stride width − .026 .042 .09 − .011 .059
 Step length .293* .327* .196 .541** -.625**
 Step time − .458** − .414** − .405** − .628** .732**
 Double support time − .475** − .458** − .391** − .592** .761**
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the TD phenotype [4]. Slower speeds and shorter step 
lengths have been also described in subjects who present 
with the freezing of gait, which is more prevalent for the 
AR phenotype [65, 66], compared with healthy controls 
[5]. Our study suggests that patients with the AR pheno-
type show slightly more impaired balance and increased 
gait disturbances compared with patients with other 
phenotypes. The limited number of participants with an 
AR phenotype included in this study may have impaired 
the ability to observe significant differences among 
phenotypes.
The convergent validity of the instrumented postural 
and gait assessments with conventional clinical tools in 
this study was comparable not only to that of the clini-
cal tools used [67] but also to that of laboratory-grade 
and gold-standard systems [68, 69]. More importantly, 
the assessments made by the instrumented tests were 
consistent (that is, had the same correlation sign) with 
those made using clinical scales. For instance, increased 
sway was associated with an increased time necessary to 
perform the 10-m Walking Test, and lower scores in the 
Tinetti Performance Oriented Mobility Assessment and 
the Functional Gait Assessment.
The ability detect the dependence of posture and gait 
performance on demographic variables, the sensitivity 
to discriminate between healthy controls and individuals 
during the middle stages of pathology, and the conver-
gent validity with clinical scales support the usefulness 
of these low-cost instrumented tools as complements to 
the clinical assessment of postural control and gait in PD 
patients. These results, together with the low-cost and 
portability of the tested devices, could also support their 
use as a low-cost alternative to laboratory-grade sys-
tems in the clinical setting, to complement postural and 
gait assessments. Despite their widespread availability, 
it is important to consider that these devices have been 
discontinued and, consequently, future studies should 
investigate the feasibility of using the latest generation of 
low-cost cameras, such as the Azure Kinect (Microsoft, 
Redmond, WA, USA), and deep learning algorithms of 
computer vision to assess human posture and gait.
Conclusions
In summary, the instrumented assessment of postural 
control and gait in individuals with PD, using low-cost 
devices, may provide feasible and complementary infor-
mation to conventional measures that are used to diag-
nose and monitor pathological progression.
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